It is also important that the BRAF-mutant melanomas may also develop PD-L1 gene amplification [10], which may result in immunoresistance, although it could increase sensitivity to ICIs targeting the PD-1/PD-L1 axis. The gene discussed is BRAF; the disease is melanoma.